Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, CT13 9NJ, UK
Depo-Provera 150 mg/ml.
| Pharmaceutical Form |
|---|
|
Sterile suspension for injection. |
Each ml of suspension contains 150 mg medroxyprogesterone acetate.
Excipients with known effect:
Methylparaben (E218) – 1.35mg
Propylparaben (E216) – 0.15mg
Sodium chloride – 3.38mg
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Medroxyprogesterone |
Medroxyprogesterone acetate exerts anti-oestrogenic, anti-androgenic and antigonadotrophic effects. |
| List of Excipients |
|---|
|
Methylparaben (E218) |
1 ml suspension for injection in a pre-filled glass syringe with halobutyl rubber plunger stopper and halobutyl rubber tip cap, packed singly.
1 ml suspension for injection in glass vials with halobutyl rubber stopper and aluminum cap with a plastic flip off in pack sizes of 1 or 25 vials.
Not all pack sizes may be marketed.
Pfizer Limited, Ramsgate Road, Sandwich, CT13 9NJ, UK
PL 00057/0965
Date of first authorisation: 27 August 1991
Date of latest renewal: 6 February 1997
| Drug | Countries | |
|---|---|---|
| DEPO-PROVERA | Australia, Brazil, Canada, Ecuador, Estonia, France, Hong Kong, Ireland, Israel, Lithuania, Mexico, Netherlands, New Zealand, Poland, Singapore, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
